Loading organizations...
Loading organizations...
XGenomes is building the sequencing technology of the future.
XGenomes has raised $3.0M across 1 funding round.
Key people at XGenomes.
XGenomes was founded in 2017 by Kalim Mir (Founder/CEO).
XGenomes has raised $3.0M in total across 1 funding round.
At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive "dark matter" of the genome. The cost of goods (consumables) of sequencing will be <$10, which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers, which be followed by a razor and blade model of selling instruments and consumables.
XGenomes was founded in 2017 by Kalim Mir (Founder/CEO).
XGenomes has raised $3.0M in total across 1 funding round.
XGenomes's investors include B Capital Group, Better Ventures, BITKRAFT Ventures, Cantos Ventures, Lever VC, Prithvi Ventures, Tectonic Capital, Vinay Hiremath.
Key people at XGenomes.
XGenomes is a biotechnology company pioneering a novel DNA sequencing technology that reads DNA in "words" rather than individual letters, enabling faster, more accurate, and cost-effective sequencing. Their integrated platform combines advanced biochemistry, hardware, and machine learning algorithms to sequence unamplified single DNA molecules directly, without complex sample preparation or bioinformatics bottlenecks. This technology targets healthcare and precision medicine by providing comprehensive genomic data—including structural variants and epigenetic information—at a consumable cost below $10, making genomic insights more accessible for early disease detection, health monitoring, and personalized interventions[1][2][3].
For an investment firm, XGenomes represents a cutting-edge innovation in genomics with a mission to transform healthcare through affordable, high-accuracy sequencing. Their approach aligns with sectors like biotech, healthcare, and life sciences, impacting the startup ecosystem by pushing the boundaries of "tough tech" in genomics and enabling new precision medicine applications. As a portfolio company, XGenomes builds a sequencing platform serving healthcare providers, researchers, and precision medicine markets, solving the problem of slow, expensive, and incomplete genomic data acquisition. Their growth is driven by validated technology, integration with machine learning, and a scalable economic model starting with service access to high-value customers and expanding to instrument sales[1][2][5].
Founded in 2017 by Kalim Mir, a seasoned genomic scientist with experience at Harvard Medical School and collaboration with George Church, XGenomes emerged from the need to overcome limitations in existing sequencing technologies. Mir’s deep expertise in human genomics and the vision to drastically reduce sequencing costs and time led to the development of a platform that sequences DNA directly on unmodified molecules. Early traction included participation in Y Combinator’s Winter 2019 batch and successful proof-of-concept demonstrations funded by SBIR grants, validating their unique approach of reading DNA "words" through super-resolution fluorescence imaging and advanced algorithms[2][5][6].
XGenomes rides the wave of increasing demand for affordable, rapid, and comprehensive genomic data to enable precision medicine, early disease detection, and lifelong health monitoring. The timing is critical as healthcare shifts toward genetically tailored treatments, and current sequencing costs and speeds limit widespread adoption. Market forces such as advances in machine learning, optical imaging, and the growing genomics market favor XGenomes’ technology. By drastically lowering costs and improving accuracy, XGenomes influences the broader ecosystem by enabling new clinical applications, expanding access to genomic data, and driving innovation in biotech and healthcare[3][6].
Looking ahead, XGenomes is poised to scale its technology from proof-of-concept to commercial deployment, expanding its customer base and refining its instrument and consumable offerings. Trends such as multi-omic integration, personalized medicine, and real-time health monitoring will shape their trajectory. As sequencing becomes more accessible and affordable, XGenomes’ influence could grow from a niche technology provider to a foundational platform in healthcare genomics, potentially transforming how health and disease are understood and managed over a lifetime[3][5].
Their mission to make multi-omic information accessible throughout an individual's lifetime ties back to their innovative approach of reading DNA "words," signaling a paradigm shift in sequencing technology and its application in healthcare.
XGenomes has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2019 | $3.0M Seed | B Capital Group, Better Ventures, BITKRAFT Ventures, Cantos Ventures, Lever VC, Prithvi Ventures, Tectonic Capital, Vinay Hiremath |
